The evolving role of oestrogen receptor beta in clinical breast cancer

Breast Cancer Research

Volumn 10, Issue 5, 2008, Pages

  Speirs, Valerie ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; ESTROGEN RECEPTOR BETA; TUMOR PROTEIN;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CELL NUCLEUS; CHEMISTRY; COHORT ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MORTALITY; NEOPLASM; NOTE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL NUCLEUS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYTOPLASM; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 59449105904     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2140     Document Type: Editorial

References (9)

1. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perrachio L, Venturo I, Nistico C, Fabi A, Buglioni S, Giorgio Natali P, Mottolese M. A divergent role for estrogen receptor beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008, 10:R74. 10.1186/bcr2139, 18771580.
2. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V. Nuclear and cytoplasmic expression of ERβ1, ERβ2, and ERβ5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008, 14:5228-5235. 10.1158/1078-0432.CCR-07-4528, 18698041.
3. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008, 26:3727-3734. 10.1200/JCO.2007.14.2968, 18669459.
4. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours. Br J Cancer 2006, 95:616-626. 10.1038/sj.bjc.6603295, 16880783.
5. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A. The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer. J Clin Pathol 2004, 57:523-528. 1770285, 15113861, 10.1136/jcp.2003.008599.
6. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother Pharmacol 2005, 56(Suppl 1):21-26. 10.1007/s00280-005-0107-3, 16273360.
7. Jensen EV, Cheng G, Palmieri C, Saji S, Mäkelä S, Van Noorden S, Wahlström T, Warner M, Coombes RC, Gustafsson JA. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001, 98:15197-15202. 65006, 11734621, 10.1073/pnas.211556298.
8. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 2002, 197:155-162. 10.1002/path.1077, 12015738.
9. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS. Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003, 27:1502-1512. 10.1097/00000478-200302000-00021, 14657709.